VANCOUVER, British Columbia, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE:
CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), announces its subsidiary Natural Ventures has
signed a definitive agreement for an annual purchase order of a minimum total of USD $4,000,000.
The Company will cultivate, manufacture, package and distribute for the Puerto Rico based dispensary network
from its fully licensed, state compliant facility. The products are white labelled under the dispensaries brand and delivered on a
weekly basis. Initial purchase orders over $400,000 USD have been fulfilled in February and with weekly increases in the Puerto
Rican medical patient base, both companies anticipate demand to increase heading into the Q2 2019.
“Chemesis has built a strong relationship with this retail focused team, and we will ensure we supply their
dispensaries with high-quality cannabis products,” said CEO of Chemesis, Edgar Montero. “Natural Ventures has continued to solidify
its reputation as a high-quality cultivator, and manufacturer of cannabis products and we see this purchase order as validation.
Furthermore, the Company expects to see an increase in monthly purchase orders, as more dispensaries are opened around the
island.”
Natural Ventures began fulfilling purchase orders in February 2019 and is providing the vendor with edibles,
vaporizers, lotions, beverages, and flower.
Due to the competitive nature of the cannabis market in Puerto Rico, the Company will not disclose who the
vendors are at this time.
On Behalf of The Board of Directors
Edgar Montero
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently
operating within California, Puerto Rico, and Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and
retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its
products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to
provide consumers with quality cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering
quality product to its consumers from seed to sale.
Investor Relations:
ir@chemesis.com
1 (604) 398-3378
Social Media:
Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
CaliforniaSap.instagram
Jay&SB.instagram
Forward-Looking Information: This news release contains "forward-looking
information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and
future of the Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in
Colombia. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there
can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on
forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results,
performance and developments to differ materially from those contemplated by these statements depending on, among other things, the
risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to
carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not
intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes
that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations
will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are
made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
